Look at their financials closer. They just got rid of their toxic debt. They had a gross profit, but a net loss after marketing. GACP just agreed to pay the marketing bill for up to 3% of the profits of new business over the next 3 years. GACP also agreed to open 10 clinics to add to new business - very good for both parties. The result is they should be profitable either this next q or the q ending in June. Think about what being profitable will do to the stock price - with or without FDA approval.
The $5 mil deal was something similar to an insider buy. It gave USRM cash to grow their business, but GACP was just got a huge benefit in return for helping USRM restructure. As stockholders, we should be pretty excited about this. We now have a vested partner with financial means.
News 
Market Data 
Discover 
AI
